Nurse Practitioner in Orangevale, CA Accepting Medicare
3 Nurse Practitioner nurses found. Showing 1 - 3
 Khanh Hoai Nguyen, NP Nurse Practitioner - Family Medicare: Not Enrolled in Medicare Practice Location: 8548 Stratus Dr, Orangevale, CA 95662 Phone: 916-206-6309 |
Ross William Lauger, FNP Nurse Practitioner - Family Medicare: Not Enrolled in Medicare Practice Location: 9267 Greenback Ln, Suite C-2, Orangevale, CA 95662 Phone: 916-539-1449 Fax: 888-990-1397 |
 Cynthia Jean Williams, FNP Nurse Practitioner - Family Medicare: Accepting Medicare Assignments Practice Location: 9490 Madison Ave, Orangevale, CA 95662 Phone: 916-238-5469 |
News Archive
Rohto launches AFC Medirepair with Signum's compound Arazine in Japan
Signum Biosciences announced that its partner, Rohto Pharmaceutical Co., Ltd., has launched AFC Medirepair® with Signum's compound Arazine™ (n-acetyl-s-farnsylcysteine or AFC) in Japan. Arazine™ is the first compound from Signum's novel anti-inflammatory platform to be commercialized from Signum's pipeline of Signal Transduction Modulators (STMs).
Hospitals with higher rates of readmissions may suffer cut in Medicare payments by 2015
Hospitals that treat more poor seniors who are on both Medicaid and Medicare tend to have higher rates of readmissions, triggering costly penalties from the Centers for Medicare and Medicaid Services, finds a new study in Health Services Research.
AARDA creates new multi-media public service campaign for AD patients
In response to a recent study that found roughly one-third of prescriptions for autoimmune disease patients go unfilled and a high level of physician mistrust exists among AD patients, the American Autoimmune Related Diseases Association, Inc. has created a new multi-media public service campaign with tools designed to help patients make informed decisions about newly-prescribed therapies and treatments.
Avanir files IND for NUEDEXTA/AVP-923 Phase II clinical trial for central neuropathic pain in MS patients
Avanir Pharmaceuticals, Inc. today announced that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin a large Phase II clinical trial of AVP-923, an investigational drug for the treatment of central neuropathic pain in patients with multiple sclerosis (MS). The FDA has acknowledged receipt of the submission and the company expects that the IND filing will be subject to standard 30-day review.
CT angiography not necessary in patients suspected with pulmonary embolism
A new study suggests that computed tomography (CT) angiography might be unnecessary in many patients suspected of having pulmonary embolism (PE), based on the results of risk assessment analysis. PE risk assessment could help reduce radiation exposure and costs associated with CT angiography. The results of the study appear in the online edition and August print issue of the journal Radiology.
› Verified 8 days ago
Registered Nurse
Nurse Practitioner
Physician Assistant
Licensed Vocational Nurse